DMD Simcyp

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Drug Metabolism and Disposition Fast Forward
First published on May 15, 2009; DOI: 10.1124/dmd.109.026500


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dmd.109.026500v1
37/8/1682    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Subramanian, M.
Right arrow Articles by Tracy, T. S.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Subramanian, M.
Right arrow Articles by Tracy, T. S.


Received for publication January 5, 2009.
Revised May 11, 2009.
Accepted for publication May 15, 2009.

CYP2D6-CYP2C9 Protein-Protein Interactions and Isoform-Selective Effects on Substrate Binding and Catalysis

Murali Subramanian 1, Michael Low 1, Charles W Locuson 2, Timothy S. Tracy 1*

1 University of Minnesota 2 Pfizer, Inc.

* Address correspondence to: E-mail: tracy017{at}umn.edu

Abstract

Abstract Cytochrome P450 (P450) protein-protein interactions have been observed with various in-vitro systems. Interestingly, these interactions appear to be isoform dependent, with some combinations producing no effect, increased or decreased catalytic activity. With some exceptions, most of the work to date has involved P450s from rabbit, rat and other animal species, with few studies including human P450s. In the studies presented herein, the interactions of two key drug metabolizing enzymes CYP2C9 and CYP2D6 were analyzed in a purified, reconstituted enzyme system for both changes in substrate binding affinity and rates of catalysis. In addition, an extensive study was conducted as to the "order of mixing" for the reconstituted enzyme system and the impact on the observations. CYP2D6 co-incubation inhibited CYP2C9 mediated S-flurbiprofen metabolism in a protein concentration dependent manner. Vmax values were reduced by up to 50%, but no appreciable effect on Km was observed. Spectral binding studies revealed a 20-fold increase in the Ks of CYP2C9 towards S-flurbiprofen in the presence of CYP2D6. CYP2C9 co-incubation had no effect on CYP2D6-mediated dextromethorphan O-demethylation. The order of combination of the proteins (CYP2C9, CYP2D6 and cytochrome P450 reductase (CPR)) influenced the magnitude of catalysis inhibition as well as the ability of increased cytochrome P450 reductase to attenuate the change in activity. A simple scheme, congruent with current results and those of others, is proposed to explain oligomer formation. In summary, CYP2C9-CYP2D6 interactions can alter catalytic activity and thus, influence in vitro-in vivo correlation predictions.


Key words: CYP2C, CYP2D, cytochrome P450, protein-protein interactions





Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2009 by the American Society for Pharmacology and Experimental Therapeutics.